Clinical trial · no report yet · Phase 3
DOMENICA
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
- NCT05201547 ↗
- Active not recruiting
- ARCAGY/ GINECO GROUP
- 48 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 27 | |
| Podcasts | 20 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Endometrial Cancer
- Interventions
- Carboplatin-Paclitaxel; Dostarlimab
- Arms
- Arm A: Dostarlimab 500 mg, every 3 weeks, 4 cycles and then 1000 mg every 6 weeks · Experimental
- Arm B: Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2, every 3 weeks, 6 cycles. · Experimental
- Enrollment
- 260 (estimated)
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor
- ARCAGY/ GINECO GROUP with GlaxoSmithKline
- Start
- Apr 15, 2022
- Primary completion
- Apr 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05201547 · updated Dec 4, 2025
Publications
linked from the registry- Secord AA, Powell MA, McAlpine J. Molecular Characterization and Clinical Implications of Endometrial Cancer. Obstet Gynecol. 2025 Nov 1;146(5):660-671. doi: 10.1097/AOG.0000000000006080. Epub 2025 Sep 18. PubMed 40966692
- Cherifi F, Ray-Coquard I, Rubio MJ, Paoletti X, Lorusso D, Choi CH, Hasegawa K, Tan DSP, Hudson E, Davis A, Tognon G, Lheureux S, Vardar Key MA, Kurtz JE, Alexandre J, Joly F. DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients. Future Oncol. 2025 Jun;21(13):1613-1623. doi: 10.1080/14796694.2025.2496133. Epub 2025 May 5. PubMed 40323277